FDA plans to remove popular Juul e-cigarettes from US markets: report


The US Food and Drug Administration is reportedly planning to pull one of the most popular brands of vaping products from the market.

The FDA could force Juul Labs Inc., the largest maker of e-cigarettes in the United States, to stop selling its products as early as this week, The Wall Street Journal reported, citing people familiar with the decision.

Juul Labs has been under FDA review since 2020, after the company asked to continue selling e-cigarette products in the United States.

The FDA was also responding to claims that Juul’s nicotine products, which were marketed with fruity flavors and celebrity endorsements, were targeting teens and causing an increase in underage tobacco use, according to the Wall Street. Log.

The FDA is reviewing all submissions from major e-cigarette companies in 2021 and 2022 to determine whether their products could entice smokers to quit and whether the benefits outweigh the health consequences for new users, including teens.

See also  FDA orders Juul e-cigarettes from US market

E-cigarettes are the most common tobacco product used by college students in the United States

A walk study by the FDA on tobacco use revealed that more than 2 million American middle and high school students used tobacco products every month in 2021.

In 2019, the FDA’s Criminal Investigations Unit launched an investigation into e-cigarette companies after the products were linked to a nationwide outbreak of vaping product-related lung disease.

Former Juul CEO Kevin Burns resigned the same year after being harshly criticized by those who feared the products were unsafe.

Juul also reduced its marketing efforts, shut down its Facebook and Instagram pages, and stopped using fruit-flavored cartridges in 2019 as a show of goodwill toward the FDA and public health concerns.

Shares of tobacco company Altria, which makes Marlboro cigarettes and owns a 35% stake in Juul, fell 8% after the announcement, according to The Guardian.

UK Time News contacted the FDA for more information, but did not hear back in time for publication.



Please enter your comment!
Please enter your name here